These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12461034)

  • 1. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
    Drago L; De Vecchi E; Lombardi A; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2002 Dec; 50(6):1059-63. PubMed ID: 12461034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
    Esel D; Doganay M; Sumerkan B
    Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
    Nicolau DP; Ambrose PG
    Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
    Cottagnoud P; Cottagnoud M; Acosta F; Flatz L; Kühn F; Stucki A; Entenza J
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):656-62. PubMed ID: 14557920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations.
    Brenciaglia MI; Fornara AM; Scaltrito MM; Braga PC
    J Chemother; 1996 Dec; 8(6):425-31. PubMed ID: 8981182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
    Ambrose PG; Grasela DM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.
    Athamna A; Massalha M; Athamna M; Nura A; Medlej B; Ofek I; Bast D; Rubinstein E
    J Antimicrob Chemother; 2004 Feb; 53(2):247-51. PubMed ID: 14688054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
    Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2002 Jun; 10(2):100-6. PubMed ID: 12702887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK; Borsos SD; Blondeau JM
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.
    Cohn ML; Waites KB
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2126-8. PubMed ID: 11408235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA; Isenberg HD; France KA; Jenkins SG
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.